Login to Your Account


Akebia takes its place in the IPO lineup, seeks $75M for anemia drug

By Randy Osborne
Staff Writer

Tuesday, February 18, 2014
With phase IIb experiments under way in nondialysis chronic kidney disease patients with anemia, Akebia Therapeutics Inc. filed for an initial public offering (IPO) that would raise as much as $75 million, as plans also firm up for a phase II study in dialysis patients, slated to begin in the first half of this year.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription